Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population-Reference-Cited by-同舟云学术

Points-to-consider documents: Scientific information on the evaluation of genetic polymorphisms during non-clinical studies and phase I clinical trials in the Japanese population

Published:2018-06 Issue:3 Volume:33 Page:141-149
ISSN:1347-4367
Container-title:Drug Metabolism and Pharmacokinetics
language:en
Short-container-title:Drug Metabolism and Pharmacokinetics

Author:

Hiratsuka Masahiro,Hirasawa Noriyasu,Oshima Yoshiteru^ORCID,Kodama Susumu,Miyata Toshio^ORCID,Dan Takashi,Takatoku Hiroyuki,Kuribayashi Hideaki,Nakamura Ryosuke,Saito Yoshiro

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmaceutical Science,Pharmacology

Reference119 articles.

1. Estimation of the warfarin dose with clinical and pharmacogenetic data;International Warfarin Pharmacogenetics Consortium;N Engl J Med,2009

2. Irinotecan pharmacogenetics in Japanese cancer patients: roles of UGT1A1*6 and *28;Sai;Yakugaku Zasshi,2008

3. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers;Shigematsu;Int J Cancer,2006

4. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis;Hulot;J Am Coll Cardiol,2010

5. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel;Zabalza;Heart,2012

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Novel Mass Spectrum-Based Assay for Simultaneous Detection of 36 Variants in the 14 Pharmacogenetic Genes for the Japanese Population;Biological and Pharmaceutical Bulletin;2023-03-01

2. Clinical study designs and patient selection methods based on genomic biomarkers: Points-to-consider documents;Drug Metabolism and Pharmacokinetics;2020-04